Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects

• Other: Saline
  
  Saline infusion for 56 minutes
• Drug: PF-02545920
  
  PF-02545920 10 mg single dose
• Other: Ketamine
  

  Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes

  PF-02545920 10 mg tablet

• Drug: PF-02545920
  
  PF-02545920 10 mg tablet single dose
• Other: Placebo
  
  Placebo tablet single dose
• Other: Ketamine
  
  Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes

• Experimental: Saline/PF-02545920
  
  Treatments are co-administered
  Interventions:
  

  • Other: Saline
  • Drug: PF-02545920
• Experimental: Ketamine/PF-02545920
  
  Treatments are co-administered
  Interventions:
  

  • Other: Ketamine
  • Drug: PF-02545920
• Placebo Comparator: Saline/Placebo
  
  Treatments are co-administered
  Interventions:
  

  • Other: Saline
  • Other: Placebo
• Experimental: Ketamine/Placebo
  
  Treatments are co-administered
  Interventions:
  

  • Other: Ketamine
  • Other: Placebo

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 21 and 45 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs). (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
• Right handed as determined by handedness questionnaire.
• Able to read and write English as a primary language.

Exclusion Criteria:

• Female subjects who are pregnant or breastfeeding.
• Any evidence of significant psychosis-like symptoms.
• Known sensitivity to ketamine.